Evidence map›Paper›PMID 26339055›Full record

ArticleJournal of virology2015

Downregulation of Toll-Like Receptor 9 Expression by Beta Human Papillomavirus 38 and Implications for Cell Cycle Control.

Laura Pacini, Claudia Savini, Raffaella Ghittoni, Djamel Saidj, Jerome Lamartine, Uzma A Hasan, Rosita Accardi, Massimo Tommasino

Open access · bronzeAbstract read
In one paragraph

Article in Journal of virology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers.

0numbers the graph read from it
0cells of the map it votes in
45citing papers in PubMed
6.1field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

45 citing papers in PubMed, 78 citations in OpenAlex.

  1. Article
  2. Article
  3. Deciphering the Role of Mast Cells in HPV-Related Cancers.International journal of molecular sciences · 2025
    Review
  4. Article
  5. Review
  6. Review
  7. Review
  8. Article
  9. Review
  10. Review
  11. Review
  12. Review
  13. Review
  14. Review
  15. Article
  16. Review
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Laura PaciniInternational Agency for Research on Cancer, Lyon, France.
Claudia SaviniInternational Agency for Research on Cancer, Lyon, France.
Raffaella GhittoniInternational Agency for Research on Cancer, Lyon, France.
Djamel SaidjInternational Agency for Research on Cancer, Lyon, France.
Jerome LamartineCentre de Génétique et de Physiologie Moléculaire et Cellulaires, CNRS UMR5534 et Université Claude Bernard Lyon 1, Lyon, France.
Uzma A HasanOncoviruses and Innate Immunity, INSERM U851, INSERM-I2V, UMS34444/US8, Université Lyon 1, Lyon, France.
Rosita AccardiInternational Agency for Research on Cancer, Lyon, France.
Massimo TommasinoInternational Agency for Research on Cancer, Lyon, France tommasino@iarc.fr.
Centre International de Recherche sur le Cancer · FRCentre National de la Recherche Scientifique · FRInserm · FR

Funding

World Health Organization 001
6 · The paper itself

Abstract

unlabelledInnate immunity is the first line of host defense against infections. Many oncogenic viruses can deregulate several immune-related pathways to guarantee the persistence of the infection. Here, we show that the cutaneous human papillomavirus 38 (HPV38) E6 and E7 oncoproteins suppress the expression of the double-stranded DNA sensor Toll-like receptor 9 (TLR9) in human foreskin keratinocytes (HFK), a key mediator of the antiviral innate immune host response. In particular, HPV38 E7 induces TLR9 mRNA downregulation by promoting accumulation of ΔNp73α, an antagonist of p53 and p73. Inhibition of ΔNp73α expression by antisense oligonucleotide in HPV38 E6/E7 HFK strongly rescues mRNA levels of TLR9, highlighting a key role of ΔNp73α in this event. Chromatin immunoprecipitation experiments showed that ΔNp73α is part of a negative transcriptional regulatory complex with IκB kinase beta (IKKβ) that binds to a NF-κB responsive element within the TLR9 promoter. In addition, the Polycomb protein enhancer of zeste homolog 2 (EZH2), responsible for gene expression silencing, is also recruited into the complex, leading to histone 3 trimethylation at lysine 27 (H3K27me3) in the same region of the TLR9 promoter. Ectopic expression of TLR9 in HPV38 E6/E7 cells resulted in an accumulation of the cell cycle inhibitors p21(WAF1) and p27(Kip1), decreased CDK2-associated kinase activity, and inhibition of cellular proliferation. In summary, our data show that HPV38, similarly to other viruses with well-known oncogenic activity, can downregulate TLR9 expression. In addition, they highlight a new role for TLR9 in cell cycle regulation. IMPORTANCE: The mucosal high-risk HPV types have been clearly associated with human carcinogenesis. Emerging lines of evidence suggest the involvement of certain cutaneous HPV types in development of skin squamous cell carcinoma, although this association is still under debate. Oncogenic viruses have evolved different strategies to hijack the host immune system in order to guarantee the persistence of the infection. Their capability to evade the immune system is as important as their ability to promote cellular transformation. Therefore, understanding the viral mechanisms involved in viral persistence is a valid tool to evaluate their potential role in human carcinogenesis. Here, we show that E6 and E7 oncoproteins from the cutaneous HPV38 downregulate the expression of the double-stranded DNA sensor TLR9 of innate immunity. We also present evidence that the HPV38-mediated downregulation of TLR9 expression, in addition to its potential impact on the innate immune response, is linked to cell cycle deregulation.

Indexed as

Cell Cycle CheckpointsCell LineCell ProliferationCyclin-Dependent Kinase 2Cyclin-Dependent Kinase Inhibitor p27Down-RegulationEnhancer of Zeste Homolog 2 ProteinHistonesHumansI-kappa B KinaseKeratinocytesMethylationp21-Activated KinasesPapillomaviridaePapillomavirus E7 ProteinsPapillomavirus InfectionsCDK2 protein, humanCDKN1B protein, humanCyclin-Dependent Kinase 2Cyclin-Dependent Kinase Inhibitor p27Enhancer of Zeste Homolog 2 ProteinEZH2 protein, humanHistonesI-kappa B Kinasep21-Activated KinasesPapillomavirus E7 ProteinsPolycomb Repressive Complex 2RNA, MessengerRNA, Small InterferingRNA, ViralTLR9 protein, humanToll-Like Receptor 9

Identifiers

PMID26339055
PMCPMC4645680
OpenAlexW1239326128

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.